Skip to content

Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015
9.95 -0.62 -5.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 14.09 In line with history 40th percentile
5-year average 30.97 · #480 of 511 in Biotechnology
P/E ratio -9.39 In line with history 44th percentile
5-year average -23.46 · forward -8.66
P/S ratio 36,171.14 In line with history 55th percentile
5-year average 32,526.41 · forward 328.21 · #389 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Summit Therapeutics (SMMT) 7.96B -9.39 14.09 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value18.77 Economic moatNone UncertaintyVery High

Trading 88.7% below Morningstar's fair value estimate.

Fair value

Summit Therapeutics Inc earns a 5-star quantitative star rating, reflecting our opinion that this share class offers a compelling opportunity for investors. The stock currently trades at a 44% discount to our quantitative fair value estimate of $18.77 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet strengthens our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 6.0, which ranks in the top 10% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Alternatively, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -4.8%, a core component of profitability, lies in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

Summit Therapeutics discussion 0 comments

Add a comment